Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2002 Jul;88(1):20-4.
doi: 10.1136/heart.88.1.20.

Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes

P G Steg  1 , B Iung, L J Feldman, D Cokkinos, J Deckers, K A A Fox, U Keil, A P Maggioni
Affiliations
Multicenter Study

Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes

P G Steg et al. Heart. 2002 Jul.

Abstract

Background: It has been suggested that patients undergoing acute intervention for coronary syndromes may not receive adequate secondary prevention.

Objective: To analyse the impact of availability and use of coronary interventions on the prescription of secondary prevention after acute coronary syndromes.

Design: Analysis of a prospective multicentre register of patients admitted to hospital for acute coronary syndromes.

Setting: A 1999 pan-European survey in 390 hospitals.

Patients: 3092 patients admitted to hospital with acute coronary syndromes (including 777 for ST elevation myocardial infarction within 12 hours of onset).

Main outcome measures: Rates of prescription of aspirin and lipid lowering agents.

Results: Performance of coronary angiography and percutaneous coronary interventions (PCI) during the hospital stay were independent predictors of prescription of aspirin at discharge (odds ratio (OR) 1.29 and 1.89, p = 0.053 and p < 0.0001, respectively). Lipid lowering agents were prescribed more often on discharge in patients admitted to hospitals with catheterisation laboratories than without (for infarction with ST elevation, 45% v 40% (NS); for other acute coronary syndromes, 46% v 36%; p < 0.05). Prescription rates were higher among patients undergoing coronary angiography or PCI than in those treated conservatively (for infarction with ST elevation, 49%, 53%, and 39%, p < 0.05; for other acute coronary syndromes, 50%, 54%, and 34%, p < 0.05). Logistic regression analysis showed that PCI was an independent predictor of prescription of lipid lowering agents at discharge (OR 1.48, p < 0.0002).

Conclusions: Contrary to expectations, invasive procedures for acute coronary syndromes are associated with higher rates of prescription of pharmacological secondary prevention.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prescription of lipid lowering treatment at discharge as a function of hospital type. Cath lab+/−, hospitals with or without a catheterisation laboratory; STE-MI, ST elevation myocardial infarction; ACS, acute coronary syndromes. *p<0.05 versus community; †p<0.05 versus cath lab.
Figure 2
Figure 2
Prescription of lipid lowering treatment at discharge as a function of invasive procedures performed during the index hospital stay. p<0.05 versus neither; †p<0.05 versus angio and neither.
See this image and copyright information in PMC

Comment in

References

    1. Antiplatelet Trialist Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by therapy in various categories of patients. BMJ 1994;308:81–106. - PMC - PubMed
    1. Lewis HD, Davis J, Archibald D, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309:396–403. - PubMed
    1. Cairns J, Gent M, Singer J, et al. Aspirin, sulphinpyrazone or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985;313:1369–75. - PubMed
    1. 4S Study Members. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383–9. - PubMed
    1. Sacks FM, Pfeffer MA, Moye LA, et al. effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001–9. - PubMed

Publication types

MeSH terms